Merck Receives Positive CHMP Opinion in the EU for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH; WHO Group 1 Pulmonary Hypertension) Merck, known as MSD…
U.S. FDA Approves AKEEGA®—First Precision Therapy for BRCA2-Mutated Metastatic Castration-Sensitive Prostate Cancer, Cutting Disease Progression by 54% Compared to Standard of Care* Johnson & Johnson announced today the U.S. Food…
Novo Nordisk A/S: EMA Recommends Higher-Dose Wegovy® for Obesity, Delivering Average Weight Loss of 20.7% Today, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued…
Updated Data for Lilly’s Inluriyo™ (imlunestrant) Reinforce Efficacy as Monotherapy and in Combination with Verzenio® (abemaciclib) in ER+, HER2– Advanced Breast Cancer Eli Lilly and Company today announced updated results…
Sarepta Therapeutics Completes Refinancing of $291 Million in 1.25% Convertible Senior Notes Due 2027 Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today announced that it…
Bio-Techne Collaborates with Wyss Center Geneva to Drive Innovation in Automated 3D Multiomics and Accelerate Spatial Biology Research Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic…
Alnylam Announces Partial Buyback of 1.00% Convertible Senior Notes Maturing in 2027 Alnylam Pharmaceuticals, the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase…
Blujepa (gepotidacin) Receives US FDA Approval as Oral Treatment for Uncomplicated Urogenital Gonorrhea (uGC) GSK plc today announced that the US Food and Drug Administration (FDA) has approved a supplemental…
FDA Grants Priority Review to Bristol Myers Squibb’s Opdivo® (nivolumab) Plus Chemotherapy for Classical Hodgkin Lymphoma Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has…
Roche Expands Automated Mass Spectrometry Portfolio with CE Mark Approval for Antibiotic Drug Monitoring, Delivering the Industry’s Broadest IVD Menu Roche announced today that it has secured CE Mark approval…
FDA Approves UPLIZNA® for Use in Adults with Generalized Myasthenia Gravis Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis…
TUKYSA Added to First-Line Maintenance Therapy Boosts Median Progression-Free Survival by More Than 8 Months in HER2+ Metastatic Breast Cancer Patients Pfizer Inc. today announced detailed results from the Phase…